Gilead: Twice-yearly lenacapavir demonstrates one-year durability in HIV prevention approaching twice that of daily oral F/TDF

Gilead disclosed data showing that twice-yearly lenacapavir achieved one-year persistence in HIV prevention nearly double that of daily oral F/TDF. Lenacapavir achieved 85.6% one-year PrEP persistence at week 52; during the 52-week study period, no HIV infections occurred in the lenacapavir group, while 1 infection was reported in the daily oral F/TDF group; serious adverse events were uncommon and unrelated to treatment, and no treatment discontinuations due to adverse events occurred in the lenacapavir group.